Needham & Company LLC Reaffirms Buy Rating for Boston Scientific (NYSE:BSX)

Key Points

• Needham & Company LLC reaffirmed a Buy on Boston Scientific with a $97 price target (about 40.15% upside), and the Street consensus remains a "Buy" with a $106 average target.
• Boston Scientific beat EPS expectations ($0.80 vs. $0.78) while reporting revenue of $5.29B (+15.9% YoY) and set Q1 2026 guidance of $0.780–0.800 and FY 2026 guidance of $3.430–3.490 EPS.
• Corporate events are mixed: late‑breaking clinical wins (EKOS HI‑PEITHO, WATCHMAN FLX CHAMPION‑AF) support growth, but CEO Michael Mahoney sold 160,901 shares (≈10.2% reduction in his holdings) and ongoing class‑action filings create headline and legal risk.

Boston Scientific (NYSE:BSX - Get Free Report)'s stock had its "buy" rating restated by equities researchers at Needham & Company LLC in a research note issued on Monday,Benzinga reports. They currently have a $97.00 price target on the medical equipment provider's stock. Needham & Company LLC's price objective would suggest a potential upside of 40.15% from the stock's current price.

Several other research analysts also recently commented on BSX. TD Cowen reduced their target price on Boston Scientific from $115.00 to $100.00 and set a "buy" rating on the stock in a report on Monday, February 2nd. Citigroup cut their price objective on Boston Scientific from $102.00 to $94.00 and set a "buy" rating for the company in a research report on Wednesday, March 11th. Wall Street Zen lowered Boston Scientific from a "buy" rating to a "hold" rating in a research note on Saturday. BTIG Research restated a "buy" rating on shares of Boston Scientific in a research note on Wednesday, February 4th. Finally, JPMorgan Chase & Co. cut their price target on Boston Scientific from $135.00 to $100.00 and set an "overweight" rating for the company in a report on Thursday, February 5th. Two research analysts have rated the stock with a Strong Buy rating, twenty-one have issued a Buy rating and two have issued a Hold rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of "Buy" and a consensus target price of $106.00.

Boston Scientific Stock Up 0.1%

Shares of NYSE:BSX opened at $69.21 on Monday. Boston Scientific has a 52 week low of $67.56 and a 52 week high of $109.50. The company has a debt-to-equity ratio of 0.46, a quick ratio of 1.08 and a current ratio of 1.62. The company's fifty day moving average is $77.45 and its 200-day moving average is $90.61. The company has a market capitalization of $102.86 billion, a PE ratio of 35.68, a P/E/G ratio of 1.07 and a beta of 0.69.

Boston Scientific (NYSE:BSX - Get Free Report) last announced its earnings results on Wednesday, February 4th. The medical equipment provider reported $0.80 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.78 by $0.02. The business had revenue of $5.29 billion during the quarter, compared to analysts' expectations of $5.29 billion. Boston Scientific had a net margin of 14.44% and a return on equity of 19.63%. The firm's revenue for the quarter was up 15.9% on a year-over-year basis. During the same quarter last year, the company posted $0.70 EPS. Boston Scientific has set its Q1 2026 guidance at 0.780-0.800 EPS and its FY 2026 guidance at 3.430-3.490 EPS. Equities research analysts predict that Boston Scientific will post 2.85 earnings per share for the current fiscal year.

Insider Activity

In related news, CEO Michael F. Mahoney sold 160,901 shares of the firm's stock in a transaction dated Monday, February 2nd. The stock was sold at an average price of $93.49, for a total value of $15,042,634.49. Following the transaction, the chief executive officer owned 1,411,735 shares in the company, valued at $131,983,105.15. This trade represents a 10.23% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 0.34% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the business. FWL Investment Management LLC acquired a new position in Boston Scientific in the second quarter valued at approximately $26,000. Steph & Co. acquired a new stake in Boston Scientific during the 3rd quarter worth $25,000. Murphy & Mullick Capital Management Corp raised its position in shares of Boston Scientific by 200.0% during the 3rd quarter. Murphy & Mullick Capital Management Corp now owns 255 shares of the medical equipment provider's stock valued at $25,000 after acquiring an additional 170 shares during the last quarter. Financial Consulate Inc. bought a new stake in shares of Boston Scientific during the 3rd quarter valued at $25,000. Finally, Swiss RE Ltd. acquired a new position in shares of Boston Scientific in the 4th quarter valued at $26,000. 89.07% of the stock is currently owned by institutional investors and hedge funds.

Trending Headlines about Boston Scientific

Here are the key news stories impacting Boston Scientific this week:

• Positive Sentiment: HI‑PEITHO: the EKOS™ Endovascular System showed superiority vs. anticoagulation alone for intermediate‑risk pulmonary embolism in a global randomized trial presented at ACC and published in NEJM — a meaningful clinical win that can accelerate adoption and revenue upside for the PE market. HI-PEITHO trial demonstrates Boston Scientific EKOS Endovascular System is superior to standard of care for treatment of acute pulmonary embolism
• Positive Sentiment: CHAMPION‑AF: the WATCHMAN FLX™ LAAC device met all primary and secondary safety and efficacy endpoints vs. NOACs (statistically superior bleeding profile), a late‑breaking result that supports broader first‑line use and long‑term growth in the LAAC market. CHAMPION-AF study of the WATCHMAN FLX device meets all primary and secondary endpoints
• Positive Sentiment: Analyst support: TD Cowen reaffirmed a Buy on BSX citing CHAMPION‑AF and LAAC market growth (PT $100 retained), which provides buy‑side validation for the clinical story. Buy Rating on Boston Scientific’s Watchman FLX Backed by Champion Trial Success and Accelerating LAAC Market Growth
• Neutral Sentiment: Q1 preview: analysts expect single‑digit EPS growth for fiscal Q1 2026; guidance and the actual print will determine whether the clinical wins translate into near‑term upside. Boston Scientific's Q1 2026 Earnings: What to Expect
• Neutral Sentiment: Conference coverage: Boston Scientific presented multiple late‑breaking trials at ACC (transcript available), increasing visibility but not immediately quantifying revenue impact. Boston Scientific Presents at American College of Cardiology 75th Annual
• Negative Sentiment: Goldman Sachs cut its price target to $93, which could pressure sentiment despite the clinical news — analyst revisions can influence near‑term flows. The Goldman Sachs Group Cuts Boston Scientific Price Target to $93.00
• Negative Sentiment: Legal overhang: multiple law firms have filed or are soliciting lead‑plaintiff claims for an alleged securities class action covering July 23, 2025–Feb 3, 2026 (lead‑plaintiff deadline May 4, 2026). Class action activity creates headline risk and potential future liabilities. INVESTOR ALERT: Boston Scientific Corporation (BSX) Investors Have Opportunity to Lead Class Action Lawsuit

Boston Scientific Company Profile

Boston Scientific Corporation NYSE: BSX is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific's activities span product development, clinical research, regulatory affairs and commercial sales.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.